[关键词]
[摘要]
目的 考察血府逐瘀胶囊联合重组人干扰素α2b注射液治疗带状疱疹后遗神经痛的临床疗效。方法 选取2016年1月—2017年9月武汉市普仁医院治疗的带状疱疹后遗神经痛患者126例作为研究对象,根据数字表法将患者随机分为对照组和治疗组,每组各63例。对照组患者肌肉注射重组人干扰素α2b注射液,100~300万单位/次,1次/2 d。治疗组在对照组治疗的基础上口服血府逐瘀胶囊,6粒/次,2次/d。两组患者均治疗30 d。观察两组患者的临床疗效,比较两组治疗前后的视觉模拟评分法(VAS)评分、临床体征改变情况和血清因子水平。结果 治疗后,对照组与治疗组总有效率分别为71.43%、87.30%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者VAS评分明显降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组患者VAS评分明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组疱止时间、结痂时间、疼痛缓解时间及痊愈时间明显短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清白细胞介素-6(IL-6)、免疫球蛋白G(IgG)水平均显著降低,白细胞介素-10(IL-10)显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组患者血清因子水平显著优于对照组,两组比较差异具有统计学意义(P<0.05)。结论 血府逐瘀胶囊联合重组人干扰素α2b注射液治疗带状疱疹后遗神经痛具有较好的临床疗效,能够改善临床症状,缓解患者疼痛程度,促进机体炎性因子平衡,具有一定的临床推广使用价值。
[Key word]
[Abstract]
Objective To investigate the clinical study of Xuefu Zhuyu Capsules combined with Recombinant Human Interferon α2b Injection in treatment of postherpetic neuralgia. Methods Patients (126 cases) with postherpetic neuralgia in Wuhan Puren Hospital from January 2016 to September 2017 were randomly divided into control and treatment groups, and each group had 63 cases. Patients in the control group were intramuscular injection administered with Recombinant Human Interferon α2b Injection, 1-3 million U/time, once every two days. Patients in the treatment group were po administered with Xuefu Zhuyu Capsules on the basis of control group, 6 grains/time, twice daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacy were evaluated, and VAS, the changes of clinical signs, and serum factor level in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 71.43% and 87.30%, respectively, and there were differences between two groups (P < 0.05). After treatment, the VAS values in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the VAS in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the time of bleb stopping, scab forming, pain relief, and healing in the treatment group were significantly shorter than those in the control group, there were differences between two groups (P < 0.05). After treatment, the serum IL-6 and IgG levels in two groups were significantly decreased, but IL-10 levels were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the levels of serum factor level in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xuefu Zhuyu Capsules combined with Recombinant Human Interferon α2b Injection in treatment of postherpetic neuralgia has a good clinical effect, can improve the clinical symptoms, relieve the pain of patients, and promote the balance of inflammatory factors, which has a certain clinical application value.
[中图分类号]
[基金项目]